Hormonal
Tirzepatide treatment in individuals with obesity and prediabetes attenuates the decline in creatinine-cystatin C-based estimated glomerular filtration rate (eGFR) and reduces urine albumin-to-creatinine ratio (UACR) compared to placebo over 176 weeks.
If you have obesity and prediabetes, treatment with tirzepatide (a once-weekly injectable medication) has been shown to help protect your kidney function over a 3-year period compared to placebo. This protection is seen as a slower decline in kidney filtration rates and a reduction in albumin in the urine, even if your kidney function is currently normal. This suggests that early intervention with this medication may offer long-term organ protection beyond just weight loss.
participants who were randomly assigned to tirzepatide experienced attenuated eGFR decline compared to those assigned to placebo during the 176-weeks follow-up. The preservation of eGFR was paralleled by a reduction in UACR.
Why this rating
Based on a randomized controlled trial (SURMOUNT-1) with a long follow-up (176 weeks) and robust statistical methods (MMRM), though the analysis is post-hoc and the population has preserved kidney function.
Source
Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From <scp>SURMOUNT</scp> ‐1 Over 176 Weeks
Hiddo J. L. Heerspink et al. · Diabetes Obesity and Metabolism · 2026
DOI 10.1111/dom.70622
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →